NextFin News - TPG-backed Asia OneHealthcare has confidentially filed for an initial public offering in Kuala Lumpur that could raise as much as 10 billion ringgit ($2.5 billion), according to people with knowledge of the matter, setting up the largest Malaysian listing since FGV Holdings' 10.4 billion ringgit offering in 2012. The draft registration was submitted to the Securities Commission Malaysia last week, the people said, asking not to be identified because the information is not yet public.
The filing is more than a single company's exit. It is the first real stress test of whether Malaysia's IPO market - freshly revived by Sunway Healthcare's 2.86 billion ringgit ($732 million) debut in March - can absorb a private-equity-scale healthcare listing, and whether investors will pay a premium for a hospital group assembled by acquisition rather than built organically. If the deal prices near the top of its range, it hands private equity a template for exiting Southeast Asia healthcare assets. If it stalls or prices down, the door slams shut just as it opened.
The Asset: A Hospital Platform Built by Acquisition
Asia OneHealthcare, formerly Columbia Asia Healthcare, is not a small operator testing the waters. After consolidating its healthcare assets across Malaysia, Indonesia and Vietnam, the holding company controls a network that, by one tally, spans 4,275 licensed beds - 2,887 of them in Malaysia. Its facilities include the tertiary hospitals of Ara Damansara Medical Centre, Bukit Tinggi Medical Centre, ParkCity Medical Centre and Subang Jaya Medical Centre, three RS Premier Hospitals in Indonesia, the Columbia Asia Hospital platform, and five super-specialty centers acquired from TE Asia Healthcare, including ALTY Orthopaedic Hospital, Beacon Hospital and Cardiac Vascular Sentral Kuala Lumpur.
The platform was assembled in stages. Hong Leong Group and TPG acquired a batch of hospitals from the group - then known as Columbia Asia Healthcare - for about $1.2 billion in 2019. In November 2023, the company agreed to buy Ramsay Sime Darby Health Care, a 50:50 joint venture between Sime Darby and Australia's Ramsay Health Care operating four hospitals in Malaysia and three in Indonesia, for 5.7 billion ringgit ($1.2 billion) in cash, with funding from the Abu Dhabi Investment Authority and Malaysia's Employees Provident Fund. It also added five super-specialty hospitals from TE Asia Healthcare.
The IPO has been telegraphed for months. In March, TPG was said to be weighing a sale or listing that could value the company at as much as 30 billion ringgit ($7.6 billion), though those discussions were preliminary and the firm could still choose to retain its stake. A confidential filing - permitted under Malaysian rules for issuers before they publicly launch a roadshow - lets the company test regulatory waters without committing to a timetable or a price. The gap between the earlier $7.6 billion valuation talk and the $2.5 billion being raised is not a contradiction: the filing size is the amount of new capital sought, not the total market value of the company.
Still, the sequencing matters. A confidential submission now, with a public launch to follow, puts Asia OneHealthcare directly in the slipstream of Sunway Healthcare - the conglomerate's healthcare arm that listed on March 18 and surged 28 percent on its debut after pricing at 1.45 ringgit a share. With 1,805 licensed beds as of January 2026, Sunway raised 2.86 billion ringgit in what was then Malaysia's biggest IPO in almost a decade. Asia OneHealthcare would be raising roughly 3.5 times as much.
The Analysis: What the Market Is Really Being Asked to Price
A Roll-Up, Not an Organic Compounder
The central question for investors is what they are actually buying: a compounder of earnings, or a portfolio of hospitals stitched together by financial engineering. Asia OneHealthcare's own statement, issued when it renamed itself in September 2024, frames the story as transformation:
Since 2020, we have embarked on a transformative journey, evolving from a secondary hospital system into a comprehensive healthcare platform. With this expansion, Asia OneHealthcare now offers a comprehensive range of healthcare services, encompassing secondary, tertiary, quaternary, and super-specialty facilities across Malaysia, Indonesia, and Vietnam.
The mechanism behind that transformation is acquisition, and the mechanism carries a valuation consequence. Buying RSDH for 5.7 billion ringgit, then adding five super-specialty centers, creates scale quickly - but it also means reported growth reflects deal flow as much as same-store performance. Sunway, by contrast, grew largely within the Sunway ecosystem, with its flagship Sunway Medical Centre alone accounting for 1,100 beds of its 1,805-bed network. An investor comparing the two must decide whether a larger, more fragmented footprint deserves a premium for scale or a discount for integration risk.
This is the classic roll-up tension. In the short run, acquisitions add beds and revenue. Over time, the market asks whether the combined entity earns a return above the cost of the capital used to buy them. That question cannot be answered from the filing alone - private healthcare operators in the region rarely disclose segment-level margins publicly - which is precisely why the roadshow pricing will matter more than usual. The market is being asked to underwrite a story it cannot fully verify in the documents.
The Valuation Gap: 1.5 Times the Per-Bed Price
The numbers make the tension concrete. On a per-bed basis, Asia OneHealthcare's 10 billion ringgit raise on 4,275 beds implies roughly 2.34 million ringgit per bed. Sunway's 2.86 billion ringgit raise on 1,805 beds came in at roughly 1.58 million ringgit per bed. The new filing is therefore asking the market to pay about 1.5 times Sunway's per-bed price - not 3.5 times, which is the ratio of the two raise sizes.
That gap is the crux of the deal. A premium is defensible if Asia OneHealthcare's super-specialty hospitals - orthopedics, cardiac, oncology - command higher margins than Sunway's general acute-care mix, and if the consolidated platform delivers procurement and staffing synergies that a standalone operator cannot. It is not defensible if the premium simply pays for scale that does not earn its cost of capital. This is where the roadshow will be won or lost: not on the number of beds, but on the earnings quality behind them.
The IPO Window Is Open - But Only Just
Timing is the second variable, and it cuts both ways. Malaysia led Southeast Asia in IPO fundraising in 2024 with $1.7 billion raised, but proceeds from first-time share sales fell 14 percent to $1.4 billion in 2025 - a reminder that emerging-market windows open on sentiment and close on it just as fast. Sunway's 28 percent first-day pop created the conditions for Asia OneHealthcare to move. A hospital name that trades up on debut tells a follow-on issuer that investors will pay for healthcare exposure, and it gives underwriters a live comparable rather than a theoretical one.
But Sunway's success is a necessary condition, not a sufficient one. A 28 percent debut pop on a 2.86 billion ringgit offering is very different from absorbing a 10 billion ringgit deal. Liquidity in the Malaysian market is finite, and a listing of this size would demand participation from the very domestic institutions already sitting in the shareholder register - the Employees Provident Fund among them. If EPF, already an existing shareholder, anchors the deal, that signals confidence. If it sits out, the absence will read as a warning.
There is also a regional dimension. TPG is not waiting around for Malaysia alone. The firm agreed in February to sell a majority stake in XCL Education, its Southeast Asian school operator, to KKR at a valuation of about $1.3 billion - a clean private sale, no public market required. That deal shows TPG has more than one exit channel and is not forced to accept a weak IPO price. It also shows the firm is actively recycling capital across the region, which strengthens its hand in negotiations but means the IPO is one option among several, not a necessity.
The Second-Order Bet: A Sector Re-Rating, or a PE Exit Template
The first-order effect of this filing is straightforward: a large healthcare company lists, TPG and its co-investors monetize part of a holding acquired for $1.2 billion in 2019, and Malaysia's exchange gets a flagship name. The second-order effect is where the real story sits. A successful Asia OneHealthcare IPO would do two things at once.
First, it would re-rate the regional hospital sector. Sunway priced at 1.45 ringgit and popped 28 percent; if Asia OneHealthcare prices at a higher multiple per bed or per revenue ringgit, it establishes a new valuation ceiling for private healthcare across Malaysia, Indonesia and Vietnam. Every other hospital operator in the region - listed or not - would be marked to that new price. Second, it would hand private equity a repeatable exit template for Southeast Asian healthcare, a sector where rising incomes and expanding middle classes have created structural demand but where exit routes have historically been thin. If the template works, expect more PE-owned hospital platforms to follow.
This is the already-priced conventional wisdom screen. The market has clearly priced "healthcare is defensive and growing" - Sunway's debut proved that. What is not yet priced is whether a roll-up built by acquisition can command a premium to an organically grown peer, and whether Malaysia's market depth can support a second large healthcare IPO within months. Those are the two gaps between what investors have rewarded and what they are being asked to fund now.
The Counter-Thesis: Paying a Premium for Scale That May Not Earn It
The strongest argument against a premium-priced deal is valuation discipline. Asia OneHealthcare is asking for 1.5 times Sunway's per-bed price for a platform that carries integration risk across three countries and three seller legacies - Columbia Asia's original platform, Ramsay Sime Darby, and TE Asia Healthcare. If the roadshow cannot demonstrate that the acquired hospitals are growing same-store earnings rather than merely consolidating reported revenue, the deal will either price down sharply or fail to clear.
There is also execution risk that a public market penalizes more harshly than a private owner would. Harmonizing procurement, staffing, IT systems and payer contracts across hospitals bought from different sellers is a multi-year task. In private hands, that integration can happen quietly. In public hands, every quarter of margin miss gets repriced immediately. The counter-thesis is not that healthcare demand is weak - it is that the specific asset being sold is a work in progress being offered at a finished-goods price.
This counter-thesis is backed by the market's own recent behavior: Malaysia's IPO proceeds fell 14 percent in 2025 even as the country led the region, which is exactly what a selective, valuation-sensitive market looks like. Investors will buy quality; they will not automatically buy size.
What to Watch: The Verdict Will Come From Pricing
My judgment: the structural demand for private healthcare in Southeast Asia is real and will not revert, but the IPO window that makes this exit possible is cyclical and can close quickly. Asia OneHealthcare is therefore a structural asset being sold into a cyclical window - and the price it achieves will tell you which force won.
Short term, watch the pricing. A deal that clears near the top of its range, with EPF or another anchor investor confirmed, would confirm that Malaysia's market can support PE-scale healthcare exits and likely pull forward other listings. Medium term, watch the post-listing trading: if the stock holds above its offer price through the first two quarters of public reporting, the roll-up thesis survives scrutiny. Long term, the structural question is whether the consolidated platform earns returns above its cost of capital - and that will only be knowable once integration is complete and margins are disclosed.
Scenarios, each with a trigger:
- Base case: the IPO prices at a discount to the earlier 30 billion ringgit valuation talk but still clears, raising 7 billion to 10 billion ringgit, and trades flat to modestly higher on debut. Trigger: a confirmed anchor investor and a roadshow that oversubscribes among domestic institutions.
- Upside case: strong foreign participation, pricing at or above the top end, and a first-day pop that re-rates the regional hospital sector. Trigger: Sunway-like demand from international funds, signaling that Malaysia is back on the global IPO map.
- Downside case: the deal prices well below range, is downsized, or is postponed. Trigger: weak book-building, absence of anchor investors, or a pullback in Sunway Healthcare's share price before the roadshow.
The single falsifying signal for the bullish read is specific and observable: if Asia OneHealthcare raises less than 7 billion ringgit - 30 percent below the 10 billion ringgit target - or prices at an implied per-bed value below Sunway's roughly 1.58 million ringgit, the thesis that Malaysia can support a premium-priced private-equity healthcare exit is wrong.
The market has rewarded healthcare. What it has not yet rewarded is a roll-up at a roll-up price - and that is the gap this IPO will close, or expose.
Explore more exclusive insights at nextfin.ai.
